Trials | Treatment | Dialysis modality | Country | No. patients | Age,years | Mean Baseline SBP,mmHg | Mean Baseline DBP,mmHg | Residual GFR,mL/min per 1.73Â m2 | Kt/V | Mean Duration on dialysis,months | follow-up, years |
---|---|---|---|---|---|---|---|---|---|---|---|
ACE-Is vs. placebo | |||||||||||
 FOSIDIAL 2006 [9] | ACE-I/Placebo | HD | France | 397 | 67 | 146 | 77 |  | 1.3 | 49.2 | 2 |
ARBs vs. placebo | |||||||||||
 SAFIR 2014 [11] | ARB/Placebo | HD | Denmark | 82 | 61 | 146 | 76 | 5.2 |  | 4.6 | 1 |
ACE-Is vs. active control | |||||||||||
 Yilmaz 2010 [18] | ACE-I/CCB | HD | Turkey | 92 | 53.8 | 157 | 88 |  | 1.4 | 47 | 1 |
 Philip 2003 [14] | ACE-I/Conventional ahtihypertensive agents | PD | China Kong Hong | 60 | 58 | 151 | 83.5 | 3.55 | 2.08 | 10.5 | 1 |
 HDPAL 2014 [20] | ACE-I/atenolol | HD | USA | 200 | 53.1 | 151 | 87.1 |  |  |  | 1 |
ARBs vs. active control | |||||||||||
 Suzuki 2008 [10] | ARB/Conventional ahtihypertensive agents | HD | Japan | 366 | 59.5 | 155 | 81 |  | 1.1 | 44.4 | 3 |
 Takahashi 2006 [8] | ARB/CCB | HD | Japan | 80 | 61 | 153 | 82 |  |  | 33.1 | 1.6 |
 OCTOPUS 2013 [19] | ARB/Conventional ahtihypertensive agents | HD | Japan | 469 | 59 | 159 | 80 |  | 1.2 | 88 | 3.5 |
 Suzuki 2004 [10] | ARB/CCB | PD | Japan | 34 | 63.5 | 165 | 76 | 4.3 | 1.97 |  | 24 |
 Wang J | ARB/Conventional ahtihypertensive agents | PD | China | 32 | 42 | 158 | 102 | 4.8 | 2.09 | 29 | 2.4 |
 Zhong H | ARB/CCB | PD | China | 44 | 45 | 134 | 83 | 4.5 | 1.97 |  | 1 |